Cancer - CSL Behring LLC

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT03805789

A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versushost disease in patients receiving hematopoietic cell transplant (MODULAATE Study)

Drug

Alpha-1 antitrypsin (AAT)

Condition

hematopoietic cell transpant patients